I see no reason why RVX should not apply for registration elsewhere while at the same time complying with whatever the FDA decides for the USA.

China would be the obvious one to go for in my opinion, and perhaps also India, where diabetes in urban communities is a big problem (about 85 million diabetics at present, almost doubling in the next 25 years) https://www.idf.org/our-network/regions-members/south-east-asia/diabetes-in-sea.html

The EMA in Europe would probably want more trial data of some type. So that should wait.